戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ipidemic drug, has been identified as a bone anabolic agent.
2 s for muscle growth during administration of anabolic agents.
3 s, but there is a clinical need for new bone-anabolic agents.
4 or use in hormone replacement therapy and as anabolic agents.
5  molecular target for identification of bone anabolic agents.
6  may represent a promising new class of bone anabolic agents.
7 mic administration of fracture-targeted bone anabolic agents.
8                                              Anabolic agents act by stimulating new bone formation.
9 ion and a target pathway for developing bone anabolic agents against osteoporosis.
10                   Growth hormone is a potent anabolic agent and salutary modulator of posttraumatic m
11 t human PTH(1-34), is likely to be the first anabolic agent approved for treating osteoporosis, despi
12 more effective resorption inhibitors and new anabolic agents are discussed.
13 nd VC, processes ameliorated by the skeletal anabolic agent BMP-7, in part through deposition of phos
14 rathyroid hormone (PTH) is an effective bone anabolic agent, but it must be administered parenterally
15  examines the mechanisms of action for these anabolic agents by detailing their receptor-activating p
16 mbination of an antiresorptive agent with an anabolic agent could be more potent than either agent al
17 nt of broken bones could be improved if bone anabolic agents could be continuously applied to a fract
18 substances, including stimulants, narcotics, anabolic agents, diuretics, peptides, and glycoprotein h
19 c modulators have the potential to act as an anabolic agent for the treatment of osteoporosis.
20      To date control strategies in detecting anabolic agents for promoting growth of food producing a
21 e of sequential therapy starting with potent anabolic agents for the patients at the highest risk, as
22 lead structure for the design of novel, bone anabolic agents for the treatment of bone disorders such
23  evaluation of a new class of potential bone anabolic agents for the treatment of osteoporosis is des
24 ors of the Wnt pathway have been proposed as anabolic agents for the treatment of osteoporosis or oth
25  templates for the development of novel bone anabolic agents for the treatment of osteoporosis.
26  evinced compound 5e as the most potent bone anabolic agent, found to be active at 1 pM, which was th
27 echnologies--such as stem cell therapy, bone anabolic agents, genetic approaches, and nanomaterials--
28 gility in DS and identify PTH as a potential anabolic agent in the adult low bone mass DS population.
29 model amphiphilic peptide), is a potent bone anabolic agent in vivo.
30                                        Novel anabolic agents in development include antibodies that t
31 an activin antagonist, have shown promise as anabolic agents in early human trials.
32                        The administration of anabolic agents in farm animals to improve meat producti
33         European Union prohibited the use of anabolic agents in food producing animals since 1988.
34 trometry method for the quantification of 59 anabolic agents in wastewater influent was developed.
35        In the past two decades, two types of anabolic agents (including three new drugs), which repre
36                                              Anabolic agents, including parent compounds and metaboli
37                                              Anabolic agents increased carcass (p = 0.002) and muscle
38 ional monotherapies with antiresorptives and anabolic agents into new combination regimens.
39 text, the comparative effectiveness of these anabolic agents is discussed in relation to other therap
40          However, their clinical use as bone anabolic agents is limited due to unwanted side effects,
41 exia, but, in combination with the use of an anabolic agent, it may slow or prevent muscle loss.
42 n of Rev-ErbAalpha, whereas stimulation with anabolic agents led to a decrease in expression.
43      By directly stimulating bone formation, anabolic agents might have greater potential than the an
44  would allow selective concentration of bone anabolic agents on a fracture surface following systemic
45       The effects of cartilage catabolic and anabolic agents on the expression of Rev-ErbAalpha were
46 f physiological changes caused by the use of anabolic agents on the molecular level, for example, by
47                       The endocrine and bone anabolic agent parathyroid hormone increased specialized
48 ve in supporting bone building with a potent anabolic agent; phosphate salt may be preferable in pati
49 an body mass to a minimum, administration of anabolic agents, recombinant human growth hormone, insul
50  support and pharmacologic intervention with anabolic agents such as growth hormone and insulin abrog
51 enic phospholipids alter the effects of bone anabolic agents, such as bone morphogenetic protein (BMP
52 gents are in clinical development, including anabolic agents, such as selective androgen receptor mod
53                                         Bone anabolic agents, such as synthetic parathyroid hormone a
54                                              Anabolic agents targeting the Wnt signaling pathway are
55  The introduction of parathyroid hormone, an anabolic agent that enhances bone formation, has been ac
56 e but do not eliminate risk of fractures, an anabolic agent that would increase bone mass and potenti
57 H) and sclerostin inhibitor (SOSTi) are bone anabolic agents that are administered to patients with o
58 eoporosis including novel antiresorptive and anabolic agents that may become available in the coming
59                                   Currently, anabolic agents that promote bone formation are increasi
60 e only Food and Drug Administration-approved anabolic agent to treat osteoporosis; however, the cellu
61  on fracture stabilization, with use of bone anabolic agents to accelerate fracture repair limited to
62 ata to bring this exciting class of skeletal anabolic agents to patient care.
63 boratory-scale sewer reactors to subject the anabolic agents to simulated realistic sewer environment
64 ility that the compounds may be used as bone anabolic agents to treat bone pathologies.
65 njugating such osteotropic ligands to a bone anabolic agent, we could acquire the ability to continuo
66                   In both groups, endogenous anabolic agents were drastically decreased by 3- to 5-fo
67                                         Most anabolic agents were likely subject to biofilm sorption
68 ested compound 18 as the most promising bone anabolic agent, which was further evaluated for in vivo
69  to lead to a new clinical paradigm in which anabolic agents will be used either alone or in combinat
70                             The combining of anabolic agents with bisphosphonates has not improved ef
71                             An orally active anabolic agent would provide a valuable alternative for